improved microbial diversity in overweight and obese subjects within a low-calorie program as compared to a normal protein diet. Another inter- esting aspect is that the two diets led to an abun- dance of Akkermansia and Bifidobacterium mi- crobiota, and to a depletion of Prevotella, just like the study in infants mentioned above. Professor Cani and his team have recently communicat- ed on the identification of a newDysosmobacter wellbionis J115T bacterium isolated from the hu- man gut. It has been detected in almost 70% of5 the healthy population and its administration in mice partially neutralized the development of di- et-induced obesity. These first results recall the work of Prof. Cani on Akkermansia muciniphila, which was at the origin of the creation in 2016 of A-Mansia Biotech, a spin-off from the Catholic University of Leuven. The Belgian company is currently awaiting its Novel Food authorization for the food supplements market and will present its latest results at the Nutriform’Business Days in Saint-Raphaël next September. MORE AND MORE OBJECTIFIED AND RECOGNIZED CANDIDATES Therefore,the microbiota continues to prove its legitimacy as a second brain. The players in this market, also involved in slimming, are pursuing their efforts to scientifically and clinically demonstrate the effectiveness of active ingredients in direct relationship with the microbiome. Just like TargEDys, the company that has recently published the results of its clinical study with Hafnia alvei HA4597® on the6 reduction of weight and waist circumference and the improvement of satiation after twelve weeks of consumption in overweight people (see Actif’s Magazine # 75). Specialized in the gut-brain axis, the spin-off highlights its expertise in identifying the mechanisms of action, in particular the hormone-mimetic action that certain bacteria may have. Years of research are lying behind these clinical outcomes. TargEDys relies on this data to convince doctors of the effectiveness of its food supplements (EnteroSatys® and Satylia®) formulated with Hafnia alvei HA4597® and, above all, of their added value compared to the use of drugs. Knowing that taking this latter is associated with a weight loss of 8.5% per year, EnteroSatys® and Satylia® can take pride in their results: - 3.6% weight loss at 3 months (clinical study) and -7% at 8 months (consumer study).With the difference that these food supplements remain natural solutions without side effects. A launch has been scheduled for the end of the year in Italy (PharmExtracta) via the network of prescribers. EnteroSatys® was voted product of the year in the #76 ECNEICSAMELC - 941 -GAM s’fitcA